Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.66 |
| ▸ | JAK2 | O60674 | 9/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10215079 | 1.00 | MET (0.66) | METJAK2CCNCCDK8JAK1 | |
| SCHEMBL10380294 | 0.92 | MET (0.56) | METJAK2JAK1TYK2JAK3 | |
| SCHEMBL488583 | 0.88 | MET (0.65) | METJAK2KCNH2 | |
| SCHEMBL5496122 | 0.88 | MET (0.65) | METJAK2JAK1TYK2JAK3 | |
| SCHEMBL30454349 | 0.88 | MET (0.65) | METJAK2KCNH2 | |
| SCHEMBL10215074 | 0.88 | MET (0.65) | METJAK2KCNH2 | |
| SCHEMBL13455023 | 0.85 | MET (0.65) | METJAK2CCNCCDK8KCNH2 | |
| SCHEMBL30453770 | 0.85 | MET (0.67) | METJAK2JAK1TYK2JAK3 | |
| SCHEMBL488376 | 0.85 | MET (0.67) | METJAK2JAK1TYK2JAK3 | |
| SCHEMBL10270841 | 0.85 | MET (0.66) | METJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885CCNC 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.